Jubilant Life Sciences Ltd

Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)

Statement of Unaudited Results for the Quarter and Nine months ended 31st December,2012

(₹ in Lacs)

STAND ALONE RESULTS						Particulars	CONSOLIDATED RESULTS					
Quarter Ended			Nine Months Ended		Year Ended		Quarter Ended			Nine Months Ended		Year Ended
December 31	September 30	December 31	December 31	December 31	March 31		December 31	September 30	December 31	December 31	December 31	March 31
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
2012	2012	2011	2012	2011	2012		2012	2012	2011	2012	2011	2012
						PART I						
						Income from operations						
81083	73654	67781	228419	192408	261764	(a) Net sales/Income from operations (Net of excise duty)	130181	121700	109051	375470	308285	425395
599	483	675	1657	1620	2343	(b) Other Operating Income	458	522	474	1421	1599	4918
81682	74137	68456	230076	194028	264107	**Total income from operations (net)**	130639	122222	109525	376891	309884	430313
72573	65490	60669	203876	168372	236145	**Expenses**	110975	101833	94048	315272	261929	364604
38302	37471	33728	111208	92076	123995	a) Cost of materials consumed	43655	43854	41140	131081	111375	149469
4967	4944	6745	14638	19081	24368	b) Purchase of traded goods	7070	7510	7817	22482	21438	30534
233	(2950)	(5188)	(4435)	(9872)	(9326)	c) Change in inventories of finished goods, work-in-progress and traded goods	2755	(5750)	(9090)	(7406)	(17528)	(18851)
8655	8113	7364	25137	18257	26976	d) Power & fuel	9183	8548	7749	26603	19572	28511
6302	6088	5606	17998	15374	20723	e) Employee benefits expenses	23834	24400	22817	71377	62396	83637
3785	3686	3228	11078	8917	13200	f) Depreciation and amortization expenses	6318	6203	5389	18427	15446	22065
10329	8138	9186	28252	24539	36209	g) Other expenses	18160	17068	18226	52708	49230	69239
9109	8647	7787	26200	25656	27962	**Profit/(Loss) from operations before other income, finance cost and exceptional items**	19664	20389	15477	61619	47955	65709
184	295	189	653	653	894	Other Income	356	346	351	1010	1058	1529
9293	8942	7976	26853	26309	28856	**Profit/(Loss) from ordinary activities before finance costs & exceptional items**	20020	20735	15828	62629	49013	67238
3959	4323	4229	12787	10890	15442	Finance costs	5435	5740	5689	17109	15104	20959
5334	4619	3747	14066	15419	13414	**Profit/(Loss) from ordinary activities after finance costs but before exceptional items**	14585	14995	10139	45520	33909	46279
7260	(4922)	15322	12762	19750	18008	Exceptional items	7098	(4380)	15549	13248	20227	34868
(1926)	9541	(11575)	1304	(4331)	(4594)	**Profit/(Loss) from ordinary activities before tax**	7487	19375	(5410)	32272	13682	11411
588	1181	2127	2818	3482	3497	Tax expense (Net)	3536	3528	888	10951	3334	6842
(2514)	8360	(13702)	(1514)	(7813)	(8091)	**Net Profit/(Loss) from ordinary activities after tax**	3951	15847	(6298)	21321	10348	4569
-	-	-		-	-	Extraordinary items (net of tax expenses)	-	-	-		-	-
(2514)	8360	(13702)	(1514)	(7813)	(8091)	**Net Profit/(Loss) for the period**	3951	15847	(6298)	21321	10348	4569
-	-	-	-	-	-	Share of Profit/(Loss) of Associate Company	-	-	-	-	-	-
-	-	-	-	-	-	Minority Interest	1282	647	1541	2951	2539	3113
(2514)	8360	(13702)	(1514)	(7813)	(8091)	**Net Profit/(Loss) after taxes, minority interest and share of profit/loss of associates**	2669	15200	(7839)	18370	7809	1456
1593	1593	1593	1593	1593	1593	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593	1593	1593
					197391	Reserves (excluding revaluation reserve)						231384
						Earnings per share before and after extraordinary items (Not annualized)						
(1.58)	5.25	(8.60)	(0.95)	(4.91)	(5.08)	**Basic (₹)**	1.68	9.54	(4.92)	11.53	4.90	0.91
(1.58)	5.25	(8.60)	(0.95)	(4.91)	(5.08)	**Diluted (₹)**	1.68	9.54	(4.92)	11.53	4.90	0.91
						PART II						
						PARTICULARS OF SHAREHOLDING						
						Public shareholding						
81166083	81166083	81166083	81166083	81166083	81166083	- Number of shares (₹ 1 each)	81166083	81166083	81166083	81166083	81166083	81166083
50.96	50.96	50.96	50.96	50.96	50.96	- Percentage of shareholding	50.96	50.96	50.96	50.96	50.96	50.96
						Promoters and promoter group Shareholding						
						a) Pledged/Encumbered						
3374000	3374000	4257000	3374000	4257000	3374000	- Number of shares	3374000	3374000	4257000	3374000	4257000	3374000
4.32	4.32	5.45	4.32	5.45	4.32	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.32	4.32	5.45	4.32	5.45	4.32
2.12	2.12	2.67	2.12	2.67	2.12	- Percentage of shares (as a % of the total share capital of the company)	2.12	2.12	2.67	2.12	2.67	2.12
						b) Non-Encumbered						
74741056	74741056	73858056	74741056	73858056	74741056	- Number of shares	74741056	74741056	73858056	74741056	73858056	74741056
95.68	95.68	94.55	95.68	94.55	95.68	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	95.68	95.68	94.55	95.68	94.55	95.68
46.92	46.92	46.37	46.92	46.37	46.92	- Percentage of shares (as a % of the total share capital of the company)	46.92	46.92	46.37	46.92	46.37	46.92
						Investor Complaints						
						Pending at the beginning of the quarter				Nil	Nil	
						Received during the quarter				18	32	
						Disposed of during the quarter				18	32	
						Remaining unresolved at the end of the quarter				Nil	Nil	

Notes:

1. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 "The Effects of Changes in Foreign Exchange Rates" . Accordingly exchange differences amounting to ₹ 2245 lacs for Q3-FY 2013 and ₹ 4560 lacs for 9 Months -FY 2013 has been amortized during the year. The accumulated debit balance as on 31st December, 2012 in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) ₹ 9512 lacs, and in Capital Work in Progress ₹ 1591 lacs is to be amortized over the balance life of loans and assets respectively.

2. The company has applied hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered Accountants of India and the credit balance in hedge reserve as at 31st December, 2012 is ₹ 509 lacs (Consolidated ₹ 528 lacs) .

3. Exceptional items include :

i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 2245 lacs (Consolidated ₹ 2245 lacs) for Q3-FY 2013 and ₹ 4560 lacs (Consolidated ₹ 4560 lacs) for 9 Months-FY 2013.

ii) Mark to Market in respect of Currency & Interest rate swap contracts at the quarter end resulting in loss/(reversal of loss) amounting to ₹ 5015 lacs (Consolidated ₹ 4951 lacs)) for Q3 FY- 2013 and ₹ 8202 lacs (Consolidated ₹ 8114 lacs) for 9 Months FY-2013.

iii) Others(net) - Loss/(gain) in consolidated accounts, includes Surplus from sale of assets & one time legal expenses, etc. amounting to (₹ 98) lacs for Q3 FY- 2013 and ₹ 574 lacs for 9 Months FY- 2013.

4. The Compensation Committee of the Board on 5th December,2012, has granted 8,84,190 options to eligible Employees/Directors of the Company and its subsidiaries as per JLL Employee Stock Option Plan,2011. Each option shall entitle the holder to acquire 1 equity share of ₹ 1 each fully paid up at ₹ 220.90 , being the market price as per SEBI guidelines.

5. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement .

6. Previous year / periods figures have been regrouped/reclassified wherever necessary.

7. The above un-audited results were , subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29th January, 2013.

For Jubilant Life Sciences Ltd.

Shyam S Bhartia

Chairman & Managing Director

Place : Noida

Dated : 29th January, 2013

Jubilant Life Sciences Ltd.

Segment wise Revenue, Results and Capital Employed
(under Clause 41 of the Listing Agreement)

(₹ in Lacs)

STAND ALONE RESULTS						Particulars	CONSOLIDATED RESULTS					
Quarter Ended			Nine Months Ended		Year Ended		Quarter Ended			Nine Months Ended		Year Ended
December 31	September 30	December 31	December 31	December 31	March 31		December 31	September 30	December 31	December 31	December 31	March 31
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
2012	2012	2011	2012	2011	2012		2012	2012	2011	2012	2011	2012
						Segment revenue						
20308	18717	15626	56266	40035	56811	a. Pharmaceuticals	66523	64954	56142	195601	155505	220131
61437	55488	52899	174009	154241	207602	b. Life Sciences Ingredients	64179	57336	53452	181489	154627	210488
81745	**74205**	**68525**	**230275**	**194276**	**264413**	**Total**	**130702**	**122290**	**109594**	**377090**	**310132**	**430619**
63	68	69	199	248	306	Less : Inter segment revenue	63	68	69	199	248	306
81682	**74137**	**68456**	**230076**	**194028**	**264107**	**Net Sales/Income from operations**	**130639**	**122222**	**109525**	**376891**	**309884**	**430313**
20308	18717	15626	56266	40035	56811	a. Pharmaceuticals	66523	64954	56142	195601	155505	220131
61374	55420	52830	173810	153993	207296	b. Life Sciences Ingredients	64116	57268	53383	181290	154379	210182
81682	**74137**	**68456**	**230076**	**194028**	**264107**	**Total**	**130639**	**122222**	**109525**	**376891**	**309884**	**430313**
						Segment results (profit(+)/loss(-) before tax and interest from each segment)						
6004	3435	3905	13752	7367	10032	a. Pharmaceuticals	15634	14193	12006	46364	29896	47088
6525	4366	6171	18753	24231	25612	b. Life Sciences Ingredients	7451	5350	5760	21561	24001	26302
12529	**7801**	**10076**	**32505**	**31598**	**35644**	**Total**	**23085**	**19543**	**17766**	**67925**	**53897**	**73390**
3959	4323	4229	12787	10890	15442	Less : i Interest(Finance costs)	5435	5740	5689	17109	15104	20959
10680	(5768)	17611	19067	25692	25690	ii. Other un-allocable expenditure(including exceptional items)	11407	(5226)	17838	20442	26169	42549
(184)	(295)	(189)	(653)	(653)	(894)	iii. Un-allocable Income(including exceptional items)	(1244)	(346)	(351)	(1898)	(1058)	(1529)
(1926)	**9541**	**(11575)**	**1304**	**(4331)**	**(4594)**	**Total Profit/(Loss) before tax**	**7487**	**19375**	**(5410)**	**32272**	**13682**	**11411**
						Capital Employed (Segment assets less Segment liabilities)						
100628	98637	94359	100628	94359	90475	a. Pharmaceuticals	466006	449107	438059	466006	438059	417359
137731	165136	167173	137731	167173	162059	b. Life Sciences Ingredients	183446	184195	179549	183446	179549	174624
238359	**263773**	**261532**	**238359**	**261532**	**252534**	**Total capital employed in segments**	**649452**	**633302**	**617608**	**649452**	**617608**	**591983**
258287	267460	259755	258287	259755	261221	Add: Un-allocable corporate assets less liabilities	45530	56951	47136	45530	47136	51154
496646	**531233**	**521287**	**496646**	**521287**	**513755**	**Total capital employed in the Company**	**694982**	**690253**	**664744**	**694982**	**664744**	**643137**